Department of Pathology, University of Illinois at Chicago, Chicago, Illinois.
Curr Protoc. 2021 May;1(5):e145. doi: 10.1002/cpz1.145.
Since December 2019, SARS-CoV-2 has spread extensively throughout the world, with more than 117 million reported cases and 2.6 million deaths (Johns Hopkins coronavirus resource center, https://coronavirus.jhu.edu/map.html). Detecting the virus is the first step in diagnosing the infection, followed by quarantine to prevent transmission. Nasopharyngeal/oropharyngeal swabs (NP/OP) and saliva are two specimen types that are most often analyzed to detect SARS-CoV-2 by molecular tests that detect viral RNA or by antigen/antibody tests that detect viral proteins and/or the host immune response against the virus. Compared to antigen/antibody tests, molecular tests are highly sensitive and specific for detecting the virus. A significant drawback is that specimen collection requirements are specific to each test and cannot be interchanged with another test. Some tests are qualified to be used on NP swabs or saliva, but not both specimen types. Even with NP swabs, a test may be qualified to detect the virus only with swabs collected in viral transport medium (VTM) but not in other media. These restrictive pre-analytic steps are disadvantageous in that a lab would have to develop and validate different tests for SARS-CoV-2 depending on the specimen type and collection media, with added setup cost, infrastructure, and training requirements. To overcome these problems, we developed and validated a cost-effective multiplex reverse-transcription real-time PCR assay that can be used to detect SARS-CoV-2 in different specimen types. The assay is highly sensitive and specific, can be used to detect the virus in saliva as well as NP swabs collected in different media such as VTM, saline, and commercial preservative fluid, and serves as one test for all applications. The protocol also describes an optimal laboratory setup and unidirectional workflow for detecting SARS-CoV-2 by RT-qPCR. © 2021 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Manual viral nucleic acid extraction from NP/OP swabs collected in different media, and from saliva Alternate Protocol 1: Low-throughput automated extraction on the Qiagen EZ1 Advanced XL machine (1-14 samples) Alternate Protocol 2: High-throughput automated extraction on the Kingfisher Flex machine (1-96 samples) Basic Protocol 2: Multiplex RT-qPCR protocol to detect SARS-CoV-2 Alternate Protocol 3: Multiplex one-step RT-qPCR protocol to detect SARS-CoV-2 with S and E gene probes labeled with the same fluorochrome.
自 2019 年 12 月以来,SARS-CoV-2 已在全球范围内广泛传播,报告病例超过 1.17 亿例,死亡 260 万例(约翰霍普金斯冠状病毒资源中心,https://coronavirus.jhu.edu/map.html)。检测病毒是诊断感染的第一步,然后进行隔离以防止传播。鼻咽/口咽拭子(NP/OP)和唾液是两种最常用于通过分子检测检测 SARS-CoV-2 的样本类型,该检测可检测病毒 RNA,或通过检测病毒蛋白和/或宿主针对病毒的免疫反应的抗原/抗体检测。与抗原/抗体检测相比,分子检测对检测病毒具有高度的敏感性和特异性。一个显著的缺点是,样本采集要求因每种检测而异,不能与另一种检测互换。一些检测有资格用于 NP 拭子或唾液,但不能同时用于两种样本类型。即使使用 NP 拭子,一种检测也可能有资格仅使用在病毒运输培养基(VTM)中收集的拭子检测病毒,但不能使用其他培养基。这些限制前分析步骤不利的方面在于,实验室将不得不根据样本类型和采集培养基开发和验证不同的 SARS-CoV-2 检测,这会增加设置成本、基础设施和培训要求。为了克服这些问题,我们开发并验证了一种经济有效的多重逆转录实时 PCR 检测方法,该方法可用于检测不同样本类型中的 SARS-CoV-2。该检测具有高度的敏感性和特异性,可用于检测唾液以及 NP 拭子,这些拭子收集于不同的介质,如 VTM、生理盐水和商业防腐剂,且作为一种检测方法适用于所有应用。该方案还描述了一种优化的实验室设置和用于通过 RT-qPCR 检测 SARS-CoV-2 的单向工作流程。
© 2021 作者。Wiley 期刊出版公司出版的《当代协议》。基本方案 1:手动从不同介质收集的 NP/OP 拭子和唾液中提取病毒核酸,或从不同介质收集的 NP/OP 拭子和唾液中提取病毒核酸。
替代方案 1:在 Qiagen EZ1 高级 XL 机器上进行低通量自动化提取(1-14 个样本)
替代方案 2:在 Kingfisher Flex 机器上进行高通量自动化提取(1-96 个样本)
基本方案 2:用于检测 SARS-CoV-2 的多重 RT-qPCR 方案
替代方案 3:用于检测 SARS-CoV-2 的多重一步法 RT-qPCR 方案,该方案使用标记有相同荧光团的 S 和 E 基因探针。